WASHINGTON — A month after advisers to the Food and Drug Administration overwhelmingly voted against the experimental ALS drug NurOwn, a Senate committee is considering a bill that would allow provisional approvals of the drug and other investigational treatments for rare, incurable diseases.
Balancing high approval standards and fast access to promising drugs has always been a wobbly act. FDA approvals can take longer than a decade, so Congress has given the FDA the power to speed approvals and allow compassionate use of unapproved drugs, and given patients the “right to try” investigational drugs without going through the FDA.
Some believe those measures suffice, but a bipartisan group of six senators believes more is needed. They’re backing a bill by Sen. Mike Braun (Ind.), the ranking Republican on the Senate Aging Committee, that would create a provisional approval path for drugs intended for serious or life-threatening diseases when there is early evidence that a drug works. The provisional status would run two years and could be renewed for a total of eight years. During that time, drug companies would be required to use registries that track patient use of drugs.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect